Results 1 to 10 of about 248 (115)
Frontal fibrosing alopecia development in two patients after botulinum toxin applications: relationship or coincidence? [PDF]
Surgical & Cosmetic Dermatology, 2021 Frontal fibrous alopecia is a primary lymphocytic scarring alopecia that is difficult to control, with a perifollicular lichenoid infiltrate marking its histology.
Mariana Abdo de Almeida +2 more
doaj +1 more source
Use of botulinum toxin in hidradenitis suppurativa [PDF]
Surgical & Cosmetic Dermatology, 2021 Introduction: Hidradenitis suppurativa (HS) is an inflamatory, chronic, recurrent, and debilitating condition. There is a lack of consensus about its treatment.
Elcilane Gomes Silva +2 more
doaj +1 more source
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]
Cochrane Database of Systematic Reviews, 2016 This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this ...
Duarte, GS +7 more
+9 more sources
Does SARS-CoV-2 vaccination affect the immediate effect of botulinum toxin? First impressions [PDF]
Surgical & Cosmetic Dermatology, 2022 Background: The SARS-CoV-2 infection has spread worldwide rapidly since its identification at the end of 2019. Globally, until April 2021, there have been more than 150 million confirmed cases of Covid-19, including over 3
Bruna Souza Felix Bravo +6 more
doaj +1 more source
Treatment of Notalgia Paresthetica with botulinum toxin A: a review [PDF]
Surgical & Cosmetic Dermatology, 2023 Notalgia Paresthetica (NP) is a sensory neuropathy characterized by itching, with or without a macule. The Botulinum Toxin A treatment may have beneficial effects on pruritus, possibly by inhibiting the substance P.
Bianca de Brito Tavares; +5 more
doaj +1 more source
Archives of Rehabilitation Research and Clinical Translation, 2021 Objectives: The objectives of this study were to evaluate whether botulinum toxin type A (BoNT-A) treatment for lower limb spasticity leads to patient goal attainment and identify factors associated with positive goal attainment and to assess the effect ...
Subbuh Choudhry, MBBS +4 more
doaj +1 more source
Botulinum toxin type A therapy for blepharospasm [PDF]
Cochrane Database of Systematic Reviews, 2020 This is an update of a Cochrane Review first published in 2005. Blepharospasm is the second most common form of focal dystonia. It is a disabling disorder, characterised by chronic, intermittent or persistent, involuntary eyelid closure, due to spasmodic contractions of the orbicularis oculi muscles.
Duarte, GS +7 more
openaire +5 more sources
Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy [PDF]
Anais Brasileiros de Dermatologia, 2014 BACKGROUND: Masseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians. OBJECTIVES: The goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy ...
Fernanda Homem de Mello de Souza Klein +4 more
doaj +2 more sources
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review
Toxins, 2021 Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis.
Emanuela Martina +4 more
doaj +1 more source
Toxins, 2021 Several studies have investigated the effect of botulinum toxin A (BoNT-A) for managing chronic musculoskeletal pain, bringing contrasting results to the forefront.
Simone Battista +7 more
doaj +1 more source